International Journal of Clinical Oncology

, Volume 17, Issue 2, pp 143–149 | Cite as

Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines

  • Takashi Takeda
  • Takuhiro Yamaguchi
  • Nobuo Yaegashi
Original Article

Abstract

Background

Kampo (Japanese herbal) medicine is the complementary and alternative medicine that is most frequently used by Japanese doctors. We studied the perceptions and attitudes of Japanese gynecologic cancer patients to Kampo medicines and analyzed the characteristics of the backgrounds of Kampo users.

Methods

A total of 476 patients with gynecologic cancer completed a self-reported questionnaire on Kampo medicine. State anxiety and trait anxiety were also assessed using the State-Trait Anxiety Inventory.

Results

It was confirmed that 22.9% of the women had used Kampo medicine. Kampo users were more likely to have had chemotherapy and were more likely to have experienced uncomfortable side effects of cancer treatment. Kampo users were more likely to believe that ‘Kampo offers relief of symptoms,’ ‘fewer side effects than Western-style medicine,’ and ‘is not less effective than Western-style medicine’ than nonusers. Kampo users expressed a stronger attitude of ‘I want to take Kampo medicine.’ Multiple risk ratio regression analysis revealed that chemotherapy (RR, 1.82; 95% CI, 1.14–2.91), lower state anxiety (RR, 0.76; 95% CI, 0.58–1.00), and higher trait anxiety (RR, 1.46; 95% CI, 1.11–1.92) were independently associated with Kampo use.

Conclusions

This study showed that slightly less than one-fourth of Japanese gynecologic cancer patients take Kampo medicine. Kampo users made more favorable comments on Kampo medicine than nonusers. Our findings suggest that the psychological characteristics of individual patients is one of the factors that can influence the usage of Kampo.

Keywords

Health survey Anxiety Complementary and alternative medicine Japan 

Notes

Acknowledgments

We thank the women who participated in this study.

Conflict of interest

No author has any conflict of interest.

References

  1. 1.
    Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRefGoogle Scholar
  2. 2.
    Ernst E, Cassileth BR (1998) The prevalence of complementary/alternative medicine in cancer: a systematic review. Cancer (Phila) 83:777–782CrossRefGoogle Scholar
  3. 3.
    Cassileth BR (1999) Complementary and alternative cancer medicine. J Clin Oncol 17:44–52PubMedGoogle Scholar
  4. 4.
    Hyodo I, Amano N, Eguchi K et al (2005) Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 23:2645–2654PubMedCrossRefGoogle Scholar
  5. 5.
    Imanishi J, Watanabe S, Satoh M et al (1999) Japanese doctors’ attitudes to complementary medicine. Lancet 354:1735–1736PubMedCrossRefGoogle Scholar
  6. 6.
    Suzuki N (2004) Complementary and alternative medicine: a Japanese perspective. Evid Based Complement Altern Med 1:113–118CrossRefGoogle Scholar
  7. 7.
    Spielberger CD (1983) Manual of the State-Trait Anxiety Inventory. Consulting Psychologists Press, Palo AltoGoogle Scholar
  8. 8.
    Nakazato K, Shimonaka Y (1989) The Japanese State-Trait Anxiety Inventory: age and sex differences. Percept Mot Skills 69:611–617PubMedCrossRefGoogle Scholar
  9. 9.
    Ishizaki T, Sasaki F, Ameshima S et al (1996) Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis. Eur Respir J 9:2691–2696PubMedCrossRefGoogle Scholar
  10. 10.
    Suzuki H, Inadomi JM, Hibi T (2009) Japanese herbal medicine in functional gastrointestinal disorders. Neurogastroenterol Motil 21:688–696PubMedCrossRefGoogle Scholar
  11. 11.
    Yu F, Takahashi T, Moriya J et al (2006) Traditional Chinese medicine and Kampo: a review from the distant past for the future. J Int Med Res 34:231–239PubMedGoogle Scholar
  12. 12.
    Sharma R, Tobin P, Clarke SJ (2005) Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6:93–102PubMedCrossRefGoogle Scholar
  13. 13.
    Mori K, Kondo T, Kamiyama Y et al (2003) Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 51:403–406PubMedGoogle Scholar
  14. 14.
    Nishioka M, Shimada M, Kurita N et al (2011) The Kampo medicine, Goshajinkigan, prevents neuropathy in patients treated by FOLFOX regimen. Int J Clin Oncol. doi:10.1007/s10147-010-0183-1
  15. 15.
    Marteau TM, Bekker H (1992) The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI). Br J Clin Psychol 31:301–306PubMedCrossRefGoogle Scholar
  16. 16.
    Chlan L, Savik K, Weinert C (2003) Development of a shortened state anxiety scale from the Spielberger State-Trait Anxiety Inventory (STAI) for patients receiving mechanical ventilatory support. J Nurs Meas 11:283–293PubMedCrossRefGoogle Scholar

Copyright information

© Japan Society of Clinical Oncology 2011

Authors and Affiliations

  • Takashi Takeda
    • 1
  • Takuhiro Yamaguchi
    • 2
  • Nobuo Yaegashi
    • 3
  1. 1.Department of Traditional Asian MedicineTohoku University Graduate School of MedicineSendaiJapan
  2. 2.Division of BiostatisticsTohoku University Graduate School of MedicineSendaiJapan
  3. 3.Department of Obstetrics and GynecologyTohoku University Graduate School of MedicineSendaiJapan

Personalised recommendations